Updates are available Correction dated 2025-04-09
Click to view Correction: https://doi.org/10.1007/s12094-025-03912-2
-
Authors
de las Heras, Blanca Martínez https://orcid.org/0000-0003-4973-0410
Rubio-Aparicio, Pedro M https://orcid.org/0000-0002-8865-9090
Rubio-San-Simón, Alba https://orcid.org/0000-0001-6426-7423
Moreno, Lucas https://orcid.org/0000-0002-0708-1670
Mazorra, Paula https://orcid.org/0009-0000-6441-2854
Almaraz, Ricardo López https://orcid.org/0000-0001-5521-9892
López, Mercedes Llempén https://orcid.org/0000-0001-8354-3307
Guill, Julia Balaguer https://orcid.org/0000-0002-7346-6499
Segura, Vanessa https://orcid.org/0000-0002-0410-9674
Bermúdez, Mar https://orcid.org/0000-0003-4630-7107
Jiménez, Irene https://orcid.org/0000-0002-3544-4045
Ramal, Désirée https://orcid.org/0009-0002-1655-3948
Cañete, Adela https://orcid.org/0000-0002-5669-5097
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 13 January 2025
First Online: 25 February 2025
Change Date: 4 April 2025
Change Type: Update
Change Details: The original online version of this article was revised to correct the funding note.
Change Date: 9 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12094-025-03912-2
Declarations
:
: B Martínez de las Heras: she received honoraria and registration payments from EUSA Pharma for educational events. PM Rubio-Aparicio: honoraria and registration payments from EUSA Pharma and Recordati Rare Diseases for educational events and travel expenses. A Rubio-San-Simon: consulting role for EUSA Pharma, Sanofi and SERB. She received honoraria from EUSA Pharma, Recordati Rare Diseases and Roche for educational events and travel expenses. L Moreno: member of a Data Monitoring Committee (DMC) for clinical trials sponsored by Novartis, Actuate Therapeutics, Shionogi, Incyte, the University of Southampton and the Royal Marsden NHS Foundation Trust; had a consulting role for Novartis, Bayer, BMS, Merck, Gilead and Shionogi, has received travel expenses from Recordati Rare Diseases and is member of the Executive Committee of SIOPEN (European neuroblastoma research cooperative group), organization which receives royalties for the sales of dinutuximab beta. His institution receives funding from sponsors for DMC participation, advisory role or conducting industry-sponsored clinical trials. M Llempén López: he received honoraria from EUSA Pharma and Gilead for educational events and travel expenses. J Balaguer: consulting role and received travel expenses from Recordati Rare Diseases Group. A Cañete: consulting role for EUSA Pharma and Norgine. She received travel expenses from Recordati. The rest of authors declare no conflict of interest.
